Modestly increased beta cell apoptosis but no increased beta cell replication in recent-onset type 1 diabetic patients who died of diabetic ketoacidosis
- First Online:
- Cite this article as:
- Butler, A.E., Galasso, R., Meier, J.J. et al. Diabetologia (2007) 50: 2323. doi:10.1007/s00125-007-0794-x
- 760 Views
Type 1 diabetes is characterised by a deficit in beta cell mass thought to be due to immune-mediated increased beta cell apoptosis. Beta cell turnover has not been examined in the context of new-onset type 1 diabetes with diabetic ketoacidosis.
Samples of pancreas were obtained at autopsy from nine patients, aged 12 to 38 years (mean 24.3±3.4 years), who had had type 1 diabetes for less than 3 years before death due to diabetic ketoacidosis. Samples of pancreas obtained at autopsy from nine non-diabetic cases aged 11.5 to 38 years (mean 24.2±3.4 years) were used as control. Fractional beta cell area (insulin staining), beta cell replication (insulin and Ki67 staining) and beta cell apoptosis (insulin and TUNEL staining) were measured.
In pancreas obtained at autopsy from recent-onset type 1 diabetes patients who had died of diabetic ketoacidosis, the beta cell deficit varied from 70 to 99% (mean 90%). The pattern of beta cell loss was lobular, with almost all beta cells absent in most pancreatic lobules; islets in lobules not devoid of beta cells had reduced or a near-normal complement of beta cells. Beta cell apoptosis was increased in recent-onset type 1 diabetes, but to a surprisingly modest degree given the marked hyperglycaemia (30 mmol/l), acidosis and presumably high NEFA. Beta cell replication, scattered pancreatic beta cells and beta cells in exocrine ducts were not increased in recent-onset type 1 diabetes.
These findings do not support the notion of active beta cell regeneration by replication in new-onset type 1 diabetes under conditions of diabetic ketoacidosis. The gluco-lipotoxicity reported in isolated human islets may be less evident in vivo.
KeywordsApoptosisBeta cell replicationHumanIsletsIslet degeneration and damageKetoacidosisPrediction of type 1 diabetesPrevention of type 1 diabetesRecent-onset type 1 diabetes
Institutional Review Board
Type 1 diabetes is characterised by hyperglycaemia due to insufficient insulin secretion. While it has become generally accepted that loss of insulin secretion in type 1 diabetes is due to autoimmune-mediated beta cell loss , the triggering mechanisms underlying the onset of the autoimmune process remain unknown. In addition, the mechanisms subserving beta cell loss in humans with type 1 diabetes are not well defined. Prior studies of type 1 diabetes of relatively recent onset in humans have reported a deficit in beta cell mass of about 70 to 100% [2–7], which declines to almost 100% in long-standing type 1 diabetes [2–4, 8, 9]. We have reported that most patients with long-standing type 1 diabetes had some detectable beta cells . Since these beta cells were associated with a low-grade lymphocytic infiltrate and had increased beta cell apoptosis, we hypothesised that ongoing beta cell turnover is present in patients with long-standing type 1 diabetes , implying a continuous source of new beta cells.
Susbsequently we had the opportunity to examine a sample of pancreas from a patient with new-onset type 1 diabetes: an 89-year-old man who had a partial pancreatectomy for a low-grade pancreatic intraepithelial neoplasia . In this case, as expected, beta cell apoptosis was increased, but surprisingly beta cell replication was also markedly increased compared with that in non-diabetic adult humans. However, it is not known whether the increased beta cell replication observed in this case was typical of new-onset type 1 diabetes. In order to address this, we examined pancreatic tissue obtained at autopsy from nine patients who died of diabetic ketoacidosis within 3 years of onset of diabetes. The fact that these pancreases were from patients with diabetic ketoacidosis is an inevitable limitation of this study, since pancreas samples from young people with recent-onset type 1 diabetes are rarely available otherwise. We quantified pancreatic fractional beta cell area, beta cell replication and beta cell apoptosis in these recent-onset cases of type 1 diabetes and in case-controlled non-diabetic samples. For comparison we also used tissue from the previously reported 89-year-old patient with recent-onset type 1 diabetes .
Human pancreatic tissue was obtained from autopsy archival paraffin blocks from nine individuals with type 1 diabetes (three male, six female, aged 12–38 years, mean age 24.3±3.4 years). We obtained Mayo Clinic Institutional Review Board (IRB) approval. Potential cases were identified by retrospective analysis of the Mayo Clinic autopsy database. These cases of type 1 diabetes were identified from autopsy archives dating from the 1930s and 1940s; in more recent years, diabetic ketoacidosis is more readily diagnosed and treated, so fortunately such patients now rarely come to autopsy. To be included, cases were required to: (1) have had a full autopsy within 24 h of death; (2) have pancreatic tissue samples of adequate size and quality; and (3) have been diagnosed with type 1 diabetes. Pancreas samples were formalin-fixed for 24 h and then paraffin-embedded. Sections of formalin-fixed, paraffin-embedded spleen from each case were also obtained: these served as an internal control for replication and apoptosis. Cases were excluded if pancreatic tissue had undergone autolysis or showed evidence of acute pancreatitis. As a positive control for increased beta cell replication, we studied newly sectioned pancreas samples from the surgical pancreatectomy of an 89-year-old man with new-onset type 1 diabetes (previously reported in ). In this case, written informed consent was obtained from the patient in compliance with the University of California, Los Angeles (UCLA) IRB guidelines.
For non-diabetic controls, IRB approval from the Mayo Clinic was obtained and human pancreas tissue from nine individuals was obtained from autopsy archival blocks. The archival tissue dated from the 1980s and 1990s. Inclusion criteria were the same as for the type 1 diabetes cases, with the exception that they were non-diabetic. Exclusion criteria were identical to those for type 1 diabetes. Sections of spleen were also available in control cases, serving as an internal control. However, the nine control tissues were from patients who had died several decades later than the diabetic cases. To ensure that the storage time of the autopsy tissue had not affected the detection of Ki67 and TUNEL staining, we studied spleen tissue, which has a known high frequency of replication and apoptosis. Sections from spleen of four non-diabetic autopsy cases dating from the 1930s were obtained and stained in parallel with spleen from the type 1 diabetes cases dating from the 1930s to 1940s and that from the controls dating from the 1980s to 1990s, using exactly the same protocol as described for pancreas. The frequency of replication (by Ki67) and apoptosis (by TUNEL) was evaluated in those sections in 20 high-power (×400) fields per case. The frequency of Ki67-positive cells per 20 high-power fields was 42±4, 66±3, 30±4 in the type 1 diabetes cases (1930s), controls (1930s) and controls (1980s), respectively. The frequency of TUNEL-positive cells per 20 high-power fields was 39±3, 38±4 and 35±3 for the same groups, respectively. We concluded from these data that no loss of antigenicity for Ki67 or TUNEL had occurred in the paraffin-embedded sections from 1930 to 1990.
Pancreatic tissue processing
Pancreas tissue was fixed in formaldehyde and embedded in paraffin for subsequent analysis as previously described [9, 10]. Sequential 5 μm sections were stained as follows: (1) insulin (peroxidase staining) and haematoxylin for light microscopy; (2) insulin and TUNEL combined (peroxidase staining); (3) insulin, Ki67 and DAPI combined (immunofluorescence); and (4) insulin, glucagon and CD3 combined (immunofluorescence).
For immunohistochemistry the following primary antibodies were used: guinea pig anti-insulin, 1:100 (Zymed Laboratories, San Francisco, CA, USA); mouse anti-glucagon, 1:2000 (Dako, Carpenteria, CA, USA); mouse Ki67, 1:200 (MIB-1; Dako); rabbit anti-CD3, 1:50 (Dako). Secondary antibodies labelled with Cy3, FITC and 7-amino 4-methylcoumarin 3-acetic acid (AMCA) were obtained from Jackson Laboratories (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) and used at dilutions of 1:100 to 1:200. For TUNEL staining, an in situ cell death detection kit (KIT AP; Roche Diagnostics, Indianapolis, IN, USA) was used.
For determination of the fractional beta cell area, the entire pancreatic section was imaged at ×40 magnification (×4 objective). The ratio of the beta cell area: exocrine area was digitally quantified as previously described [9, 10] using Image Pro Plus software (Media Cybernetics, Silver Springs, MD, USA).
To determine beta cell replication, sections of pancreas double-stained for insulin and Ki67 by immunofluorescence were examined; all islets in the section were examined and the number of Ki67-positive cells expressed in terms of cells per islet as well as in relation to the respective beta cell area. One section of pancreas from each of the diabetic and control cases was available; for the 89-year-old man, sections from four blocks were available and the mean values of the data from the four sections were calculated. To determine the extent of replicating cells associated with exocrine ducts and endothelial cells, ten random locations in each section stained by immunofluorescence for insulin, Ki67 and DAPI were imaged at ×200 magnification (×20 objective) and analysed in detail. The total number of Ki67-positive cells per section, as well as the number of beta cells co-staining with Ki67, was quantified. The number of replicating beta cells was expressed as a percentage of the total number of beta cells per case. For determination of apoptosis, we used slides double-stained for insulin and TUNEL by immunoperoxidase and analysed 100 islets per case. The number of apoptotic beta cells was expressed in terms of cells per islet as well as in relation to the respective beta cell area. One section from each of the diabetic and control cases and four sections from the 89-year-old man were available. For determination of the extent of beta cells associated with exocrine ducts, we examined sections of pancreas that had been stained for insulin by immunohistochemistry for light microscopy and counterstained with haematoxylin; the total number of cells comprising 60 exocrine ducts was counted in each case and the number of insulin-positive duct cells was expressed as a percentage of the total number of duct cells. The number of scattered individual insulin-positive cells was determined on the same insulin-stained sections; the number of individual insulin-positive cells in the entire pancreas section was counted. The size of the pancreatic tissue section in mm2 was determined using Image Pro Plus software and the number of individual insulin-positive cells was expressed as number per mm2 pancreatic tissue.
For the determination of islet size, pancreatic sections stained for insulin (peroxidase) and haematoxylin were analysed. After careful assessment of the entire pancreatic section, ten representative islets were identified. For each islet, we first measured the total islet size using Image Pro Plus software (Media Cybernetics) and then measured the insulin-positive area of each islet. Islet density was quantified by measuring the total area of the pancreas section using Image Pro Plus software (Media Cybernetics) and counting the number of islets contained within that pancreatic area. An islet was defined as a cluster of four or more insulin-positive cells.
Data are presented as mean ± SEM. For statistical comparisons we used a two-sided unpaired Student’s t test with a p value of less than 0.05 taken as significant.
Clinical characteristics of nine cases of recent-onset type 1 diabetes
Duration of diabetes
Beta cell area (%)
Cause of death
Insulitis (% of islets)
Number of islets (n)
Type 1 diabetes
Diabetes for 2 years; died of diabetic ketoacidosis
Well until 1 week before death; died of diabetic ketoacidosis
Well until 14 days before death; viral infection, died of diabetic ketoacidosis
Diabetic ketoacidosis diagnosed on admission; jaundice and death
Treated with insulin for diabetes for 3 months; died of diabetic ketoacidosis
Died at presentation of diabetic ketoacidosis
History of diabetes for 3 years; no insulin for 2 weeks plus infection; died of diabetic ketoacidosis
Diabetes undiagnosed for 12 months; died of diabetic ketoacidosis
Suicide/tetraethyl lead intoxication
Pedestrian motor vehicle accident
Golf ball to head
Ventricular fibrillation following appendectomy
Beta cell apoptosis
Beta cell replication
Insulin-positive cells in ducts and scattered insulin-positive cells
Scattered insulin-positive cells in pancreas and the percentage of insulin-positive cells in exocrine ducts have previously been considered possible markers of newly forming beta cells from pancreatic progenitor cells, although this approach has not been validated. In tissue from cases of recent-onset type 1 diabetes, there was a marked reduction in the number of insulin-positive cells in exocrine pancreatic ducts, with none seen compared with controls (0.00 ± 0.00 vs 1.01 ± 0.14%) (Fig. 2c). Similarly, there was a reduction in the frequency of individual insulin-positive cells scattered throughout the exocrine pancreas (type 1 diabetes cases 0.21 ± 0.07 vs control 1.13 ± 0.17 cells/mm2, p < 0.0001) (Fig. 2b).
In this study we studied pancreas tissue from patients with type 1 diabetes who had died from diabetic ketoacidosis and whose diagnosis of diabetes had been made less than 3 years before death. We quantified the beta cell deficit and examined beta cell turnover in these pancreases.
Prior studies have reported a similar range of beta cell deficit in patients with new-onset type 1 diabetes [2–7]. It might be anticipated that patients with diabetic ketoacidosis leading to death would have a lower residual beta cell mass than most newly presenting cases of type 1 diabetes. Indeed insulin secretion in people with treated recent-onset type 1 diabetes suggests a relatively preserved beta cell function and therefore presumably beta cell mass [13, 14]. It is perhaps surprising that individuals with as much as 30% of the normal beta cell complement should have died of diabetic ketoacidosis, given the conventional teaching that this occurs as a consequence of almost complete insulin deficiency. The most likely explanation is that not only does new-onset type 1 diabetes result from a deficit in beta cells, but also from a profound deficit in beta cell function. This postulate gains support from the partial recovery of insulin secretion and glucose homeostasis (the so-called ‘honeymoon period’) observed in many patients after insulin therapy is initiated for type 1 diabetes [15, 16]. A similar situation has recently been recognised in type 2 diabetes, where diabetic ketoacidosis is an increasingly recognised complication, particularly in African–American and Hispanic patients. Again, many of these patients no longer need insulin therapy once treated [17, 18]. Collectively these data emphasise the complex relationship between beta cell mass, beta cell function and insulin sensitivity. In the setting of a normal beta cell mass, insulin resistance does not lead to hyperglycaemia or subsequent metabolic decompensation to diabetic ketoacidosis. However, once beta cell mass declines to approximately 50% of normal, impaired fasting glucose and glucose intolerance may develop [19, 20]. With each further decrement in beta cell mass, there appears to be a much more marked increase in blood glucose, implying an adverse interaction between declining beta cell mass, impaired beta cell function and increasing insulin resistance . The present study suggests that a deficit in beta cell mass of 70% or more in the context of the adverse beta cell environment present in type 1 diabetes is sufficient to lead to diabetic ketoacidosis.
The mechanisms subserving loss of beta cells in type 1 diabetes remain unclear. While there is little doubt that there is an autoimmune basis for type 1 diabetes, the trigger(s) that promote this cycle of autoimmunity remain unknown. Consistent with some prior reports, we noted a lobular distribution of beta cell loss and a tendency for a more readily detectable lymphocytic infiltrate in patients with a younger age of onset (100% of patients <20 years old vs 30% of those >20 years old at onset) [2–4, 6, 7]. Some lobules were characterised by islets that were almost completely devoid of beta cells, yet were adjacent to lobules containing islets with a near-normal complement of beta cells. Indeed most islets in these new-onset cases of type 1 diabetes could be subdivided into those with no detectable beta cells (approximately 80–90%) and those with a normal complement of beta cells (approximately 10–20%). This implies that the loss of beta cells is analogous to that in vitiligo, with a near-complete loss in some lobules and minimal loss in other lobules, rather than a general loss throughout the pancreas. Such a mechanism is consistent with an autoimmune model with islets upstream of activated lymph nodes vulnerable to accelerated beta cell loss.
Perhaps the most surprising finding in the present study is the relatively modest increase in frequency of beta cell apoptosis in the islets with a near-normal complement of beta cells. While this is consistent with the notion of a regional autoimmune process, the relatively low frequency of beta cell apoptosis is a testament to the effectiveness of the beta cell anti-apoptotic mechanisms in vivo compared with those in isolated human islets. Isolated human islets exposed to a glucose concentration of 30 mmol/l [21, 22] or a fatty acid concentration of more than 2 mmol/l  have a marked increase in beta cell apoptosis. In these patients with diabetic ketoacidosis, the beta cells within the islets with a near-normal complement of beta cells were exposed to marked hyperglycaemia (∼30 mmol/l) and (presumably) to NEFA concentrations in excess of 2 mmol/l. Moreover, these islets were exposed to the acidosis present in diabetic ketoacidosis. These data serve to support caution when extrapolating findings, such of those on gluco-lipotoxicity carried out in isolated islets [21, 22], to the in vivo situation, where the beta cell anti-apoptosis mechanisms appear to be much more effective than in isolated islets.
A primary goal of the present studies was to evaluate the frequency of beta cell replication in new-onset type 1 diabetes. Beta cell replication was not increased in these cases of recent-onset type 1 diabetes complicated by diabetic ketoacidosis. This finding is in contrast to those in pancreas samples obtained surgically from an 89-year-old man with recent-onset type 1 diabetes, which are reconfirmed here in newly sectioned slides studied in parallel with tissue from recent-onset cases with diabetic ketoacidosis .
There are several possible explanations for this discrepancy. The pancreatic intraepithelial tumour in the 89-year-old man could have theoretically expressed a factor or factors that promoted beta cell replication. Although we cannot rule it out, this explanation seems unlikely, given that the frequency of beta cell replication in this case was not related to distance from the pancreatic tumour (in contrast to the situation in human gastrinomas ). Another possibility is that the capacity for beta cell replication in response to beta cell destruction in type 1 diabetes in the elderly is different from that in younger patients. At present we have insufficient data to address that possibility, although in general attempted tissue regeneration through cell replication would not be expected to be more prominent in elderly than in younger patients. While controversial, it is thought that onset of type 1 diabetes in the older population may be a different disease from that with onset in younger individuals .
Perhaps the most likely explanation for the difference in beta cell replication between the people with recent-onset type 1 diabetes who died of diabetic ketoacidosis and the previously reported surgical case is the deleterious consequences of the ketoacidosis. In support of this, we note that there was a modest decrease in beta cell replication in the pancreatic endothelial cells from new-onset type 1 diabetes cases vs those from controls. Beta cells are particularly prone to oxidative stress , which is induced by high glucose concentrations and acidosis. Cell cycle progression is dependent on normal ion channel function , which is compromised in acidosis. In culture, cell replication is decreased under conditions of acidosis. Therefore, while it is impossible to know with certainty why beta cell replication was if anything decreased in the new-onset type 1 diabetes cases (vs non-diabetic controls) and was certainly decreased in comparison with the 89-year-old man with new-onset type 1 diabetes and partial pancreatectomy, suppression of adaptive beta cell replication by diabetic ketoacidosis is a plausible explanation.
The conclusions of the present study have therefore to be tempered to acknowledge that while we report no evidence of increased beta cell replication in recent-onset type 1 diabetes after death due to diabetic ketacidosis, this may not reflect the status in these patients prior to the onset of metabolic decompensation. Indeed, in a recent report, pancreas tissue procured from non-diabetic brain-dead donors who were positive for islet autoantibodies revealed occasional islets with lymphocytic infiltration and increased beta cell replication . These intriguing findings are consistent with the postulate that low levels of pro-inflammatory cytokines may foster beta cell replication rather than beta cell apoptosis . The findings of others , confirmed here, of greater heterogeneity in islet size, most notably with some markedly enlarged islets in new-onset type 1 diabetes, are also consistent with prior efforts at beta cell regeneration through increased intra-islet beta cell replication eventually being overcome by increased beta cell destruction.
In summary, pancreas tissue in humans with recent-onset type 1 diabetes who died of diabetic ketoacidosis reveals a lobular pattern of beta cell loss, with most islets containing no detectable beta cells and those not devoid of beta cells having an apparently normal complement of beta cells. The deficit in beta cells in these cases varied from ∼70 to 99%, with a modestly increased frequency of beta cell apoptosis in the remaining beta cells despite markedly increased blood glucose (and presumably NEFA) and acidosis. In these pancreases, which were procured after death from ketoacidosis, beta cell replication was not increased and scattered pancreatic beta cells and beta cells within exocrine ducts were decreased compared with non-diabetic control tissue.
The present studies were funded by the Larry Hillblom Foundation and the Juvenile Diabetes Research Foundation. We acknowledge the excellent suggestions from our colleagues at the Larry Hillblom Islet Research Center, specifically A. Bhushan, L. Haataja, T. Gurlo and K. Maedler. We are particularly indebted to B. Lui for administrative support.
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.